To ‘Keep Pace with Viral Evolution,’ Invivyd Is Also Evolving (Again)

Invivyd announced the selection of a candidate called VYD222 to move forward into the clinic, at the expense of previous focus NVD200, according to a press release. The new star in the company’s pipeline is one of the components of the older treatment and was also engineered from the biotech’s original mAb adintrevimab.